Please try another search
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d’Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Charles B. Shoemaker | - | 2012 | Member of Infectious Disease Scientific Advisory Board |
Steven A. Shallcross | 60 | 2015 | CEO, CFO, Treasurer, Corporate Secretary & Director |
Jeffrey Jay Kraws | 57 | 2006 | Independent Non-Executive Chairman |
Thomas J. Louie | - | 2014 | Member of C Difficile Clinical Advisory Board |
Curtis Donskey | - | 2014 | Member of C Difficile Clinical Advisory Board |
Ciarán P. Kelly | - | 2014 | Member of C Difficile Clinical Advisory Board |
Richard Hodin | - | 2020 | Member of Intestinal Alkaline Phosphatase Clinical Advisory Board |
Thomas W. Dubensky | 64 | 2022 | Member of Scientific Advisory Board |
Josep Tabernero | - | 2022 | Member of Scientific Advisory Board |
Mark S. Blumenkranz | 71 | 2022 | Member of Scientific Advisory Board |
Ennio Antonio Chiocca | - | 2022 | Member of Scientific Advisory Board |
Daniel DiMaio | - | 2022 | Member of Scientific Advisory Board |
Mark H. Wilcox | - | 2014 | Chairman of C Difficile Clinical Advisory Board |
Jeffrey Alan Wolf | 60 | 2006 | Independent Director |
John Monahan | 77 | 2011 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review